MA31562B1 - Macrocycles et leurs utilisations - Google Patents

Macrocycles et leurs utilisations

Info

Publication number
MA31562B1
MA31562B1 MA32463A MA32463A MA31562B1 MA 31562 B1 MA31562 B1 MA 31562B1 MA 32463 A MA32463 A MA 32463A MA 32463 A MA32463 A MA 32463A MA 31562 B1 MA31562 B1 MA 31562B1
Authority
MA
Morocco
Prior art keywords
macrocycles
diseases
prevention
improvement
useful
Prior art date
Application number
MA32463A
Other languages
English (en)
Inventor
Philipp Krastel
Matthew J Lamarche
Roger Aki Fujimoto
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA31562B1 publication Critical patent/MA31562B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

LA PRÉSENTE INVENTION CONCERNE DES COMPOSÉS ORGANIQUES QUI SONT UTILES POUR LE TRAITEMENT, LA PRÉVENTION ET/OU L'AMÉLIORATION DE MALADIES.
MA32463A 2007-06-04 2009-12-30 Macrocycles et leurs utilisations MA31562B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US94177707P 2007-06-04 2007-06-04

Publications (1)

Publication Number Publication Date
MA31562B1 true MA31562B1 (fr) 2010-08-02

Family

ID=40094226

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32463A MA31562B1 (fr) 2007-06-04 2009-12-30 Macrocycles et leurs utilisations

Country Status (24)

Country Link
US (2) US8476224B2 (fr)
EP (1) EP2170907A2 (fr)
JP (1) JP2010529076A (fr)
KR (1) KR101202483B1 (fr)
CN (1) CN101772506B (fr)
AR (1) AR066865A1 (fr)
AU (1) AU2008258639B2 (fr)
BR (1) BRPI0812340A2 (fr)
CA (1) CA2688621A1 (fr)
CL (1) CL2008001613A1 (fr)
CO (1) CO6270222A2 (fr)
CR (1) CR11158A (fr)
EA (1) EA200901613A1 (fr)
EC (1) ECSP099836A (fr)
GT (1) GT200900310A (fr)
IL (1) IL202285A0 (fr)
MA (1) MA31562B1 (fr)
MX (1) MX2009013214A (fr)
NZ (1) NZ581917A (fr)
PE (1) PE20090318A1 (fr)
TN (1) TN2009000495A1 (fr)
TW (1) TW200902540A (fr)
WO (1) WO2008148754A2 (fr)
ZA (1) ZA200908262B (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201400280A1 (ru) 2007-12-12 2014-08-29 Новартис Аг Аминотиазолы и их применение
EP3528786B1 (fr) * 2016-10-21 2023-04-05 Xellia Pharmaceuticals ApS Formulations liquides de daptomycine
CN109485617B (zh) * 2018-12-11 2023-01-31 贵州永诺菲特生物制药有限公司 一种n-甲基-2-异丙基-4-噻唑甲胺的制备方法
WO2024044751A2 (fr) * 2022-08-26 2024-02-29 Wake Forest University Health Sciences Inhibiteurs de peroxyrédoxine 3 et procédés d'utilisation pour le traitement du cancer

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0451486B1 (fr) * 1990-03-08 1995-04-19 GRUPPO LEPETIT S.p.A. Antibiotique GE 2270 facteurs B1, B2, C1, D1, D2, E et T
DE4011378A1 (de) 1990-04-07 1991-10-10 Hausen Auto Kabel Gmbh & Co Kg Anschlussklemme fuer akkumulator oder dergleichen
IL100572A (en) 1991-01-03 1997-01-10 Lepetit Spa Amides of antibiotic ge 2270 factors their preparation and pharmaceutical compositions containing them
DK0529410T3 (da) * 1991-08-30 1998-05-11 Biosearch Italia Spa Antibiotikum GE 2270 faktor C2a
JP2000505438A (ja) * 1996-02-14 2000-05-09 バイオサーチ・イタリア・ソチエタ・ペル・アチオニ 抗生物質ＧＥ２２７０因子Ｃ▲下２ａ▼、Ｄ▲下２▼およびＥの誘導体
JPH1059997A (ja) * 1996-08-22 1998-03-03 Microbial Chem Res Found アミチアマイシンアミド誘導体
BR0305070A (pt) * 2002-06-17 2004-09-21 Vicuron Pharm Inc Uso de derivado amida de ge 2270 fator a3 para tratamento da acne
US20050106159A1 (en) * 2003-08-12 2005-05-19 Thompson Stuart A. Campylobacter jejuni outer membrane protein immunogenic composition
PE20080103A1 (es) * 2006-05-31 2008-04-03 Novartis Ag AMINOTIAZOLES COMO MODULADORES DEL FACTOR DE ELONGACION EF-Tu
EP2097423B1 (fr) * 2006-12-20 2011-03-02 Novartis AG Dérivés macrocycliques du aminothiazole, leur utilisation comme antibacteriens et procédés pour leur preparation

Also Published As

Publication number Publication date
CA2688621A1 (fr) 2008-12-11
ECSP099836A (es) 2010-01-29
AU2008258639A1 (en) 2008-12-11
TN2009000495A1 (en) 2011-03-31
KR20100021496A (ko) 2010-02-24
KR101202483B1 (ko) 2012-11-16
US20130252883A1 (en) 2013-09-26
ZA200908262B (en) 2010-08-25
AU2008258639B2 (en) 2012-07-05
GT200900310A (es) 2010-05-21
US20090186830A1 (en) 2009-07-23
PE20090318A1 (es) 2009-04-17
BRPI0812340A2 (pt) 2015-01-27
CO6270222A2 (es) 2011-04-20
US8476224B2 (en) 2013-07-02
CL2008001613A1 (es) 2009-05-15
CN101772506B (zh) 2014-02-12
EP2170907A2 (fr) 2010-04-07
WO2008148754A2 (fr) 2008-12-11
WO2008148754A3 (fr) 2009-03-05
CR11158A (es) 2010-01-20
IL202285A0 (en) 2010-06-16
AR066865A1 (es) 2009-09-16
TW200902540A (en) 2009-01-16
JP2010529076A (ja) 2010-08-26
MX2009013214A (es) 2010-01-15
NZ581917A (en) 2011-04-29
CN101772506A (zh) 2010-07-07
EA200901613A1 (ru) 2010-06-30
US8691756B2 (en) 2014-04-08

Similar Documents

Publication Publication Date Title
MA31767B1 (fr) Composes organiques et leurs utilisations
MA30392B1 (fr) Composes organiques et leurs utilisations
MA33155B1 (fr) Composes organiques et leurs utilisations
EA201100505A1 (ru) Органические соединения для применения для лечения бактериальных инфекций
EA200901166A1 (ru) Соединения и композиции в качестве модуляторов активности gpr 119
ATE477252T1 (de) Substituierte diazepane als antagonisten an orexinrezeptoren
TW200631583A (en) Substituted pteridines for the treatment of inflammatory diseases
MA30485B1 (fr) Aminothiazoles et leurs utilisations
MA31167B1 (fr) Inhibiteurs de l'activite de akt
MA31906B1 (fr) Inhibiteurs de la replication du virus de limmunodeficience humaine
NO20092470L (no) Substituerte diazepanforbindelser som orexinreseptorantagonister
MA28681B1 (fr) 3-aminocyclopentanecarboxamides utiles comme modulateurs de récepteurs de chimiokines
MA31147B1 (fr) 4-phenyl-pyrane-3.5-diones ,4-phenyl-thiopyrane-3.5- diones et cyclohexanetriones en tant que nouveaux herbicides
MA30358B1 (fr) Quinazolines pour l'inhibition de pdk1
MA31451B1 (fr) Antagonistes des recepteurs de l'orexine de pyridyl piperidine.
MA31117B1 (fr) Composes tricycliques et leur utilisation comme modulateurs du recepteur de glucocorticoïdes
EA200900828A1 (ru) Соединения и композиции в качестве ингибиторов активности каннабиноидного рецептора 1
DE602004013563D1 (de) Rantagonisten
JO2355B1 (en) Hereditary calcitonin polypeptide receptor antagonists
MA28680B1 (fr) 3-aminocyclopentanecarboxamides utiles comme modulateurs de récepteurs de chimiokines
MA30497B1 (fr) Anticorps et immunco-conjugues, et leurs utilisations.
MX2009006536A (es) Compuestos de heteroaril-heteroarilo como inhibidores de cdk para el tratamiento de cancer, inflamacion e infecciones virales.
EA200600048A1 (ru) Производные бензазепина, используемые для лечения заболеваний, ассоциированных с 5-ht-рецептором
MA33534B1 (fr) Anticorps humains d'affinité élevée dirigés contre l'angiopoïétine 2 humaine
ATE509019T1 (de) Benzodiazepinspirohydantoine als cgrp- rezeptorantagonisten